GSA Capital Partners LLP Invests $446,000 in CareDx, Inc. $CDNA

GSA Capital Partners LLP bought a new position in CareDx, Inc. (NASDAQ:CDNA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 30,670 shares of the company’s stock, valued at approximately $446,000. GSA Capital Partners LLP owned approximately 0.06% of CareDx at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CDNA. Allworth Financial LP acquired a new position in CareDx in the second quarter worth approximately $40,000. State of Alaska Department of Revenue acquired a new position in shares of CareDx in the 3rd quarter worth $43,000. RiverPark Advisors LLC acquired a new stake in shares of CareDx during the second quarter worth $149,000. Tower Research Capital LLC TRC lifted its holdings in shares of CareDx by 120.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after purchasing an additional 4,160 shares during the last quarter. Finally, AlphaQuest LLC boosted its position in shares of CareDx by 40.0% in the 2nd quarter. AlphaQuest LLC now owns 9,576 shares of the company’s stock valued at $187,000 after purchasing an additional 2,736 shares during the period.

Wall Street Analyst Weigh In

CDNA has been the topic of several recent analyst reports. Craig Hallum downgraded CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective on the stock. in a report on Tuesday, January 6th. Wall Street Zen downgraded shares of CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. BTIG Research boosted their price target on shares of CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Wells Fargo & Company raised their price objective on shares of CareDx from $14.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Finally, Zacks Research upgraded shares of CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th. Three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $26.67.

Key Stories Impacting CareDx

Here are the key news stories impacting CareDx this week:

• Positive Sentiment: Revenue beat and robust top-line growth: Q4 revenue of $108.39M topped consensus (~$102.8M) and rose ~25% year-over-year — a sign demand remains strong for CareDx’s transplant diagnostics and services. CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say
• Positive Sentiment: FY‑2026 revenue guidance came in slightly above Street expectations (range ~$420M–$444M vs. consensus ~$417.5M), giving investors a clearer growth runway and partially offsetting the EPS shortfall. Press Release / Slide Deck
• Neutral Sentiment: Internal leadership change: COO Keith Kennedy will also assume CFO responsibilities — an operational continuity move but one that raises questions about long‑term finance leadership and succession. CareDx Announces Appointment of Keith Kennedy as COO and CFO
• Negative Sentiment: EPS missed meaningfully: GAAP EPS was $0.12 versus consensus ~$0.24, and EPS declined from $0.18 year‑ago — investors often punish earnings misses even when revenue beats, especially for profitability trajectory. CareDx (CDNA) Q4 Earnings Miss Estimates
• Negative Sentiment: Street profitability expectations remain cautious: some analysts now model negative full‑year EPS (consensus commentary showed materially lower EPS expectations for the fiscal year), which may keep valuation pressure despite revenue strength. MarketBeat CDNA Overview

CareDx Stock Up 2.4%

Shares of NASDAQ:CDNA opened at $19.25 on Wednesday. The firm has a fifty day moving average of $19.68 and a two-hundred day moving average of $16.74. The firm has a market capitalization of $990.03 million, a P/E ratio of 16.18 and a beta of 2.51. CareDx, Inc. has a 12-month low of $10.96 and a 12-month high of $22.95.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). The company had revenue of $108.39 million during the quarter, compared to analyst estimates of $102.76 million. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The company’s revenue was up 25.2% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. Equities research analysts expect that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Insider Buying and Selling at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the completion of the sale, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at $12,641,089.80. This trade represents a 3.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 29,636 shares of company stock worth $625,949. 4.40% of the stock is owned by company insiders.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.